Browse the evidence

High levels of physical activity, frequent monitoring of body weight, and consumption of a reduced-calorie diet are associated with long-term weight loss.

Encourage patients to maintain high physical activity and monitor their weight regularly for effective weight management.

In the 10-mg tirzepatide group, 56% of participants achieved resolution of MASH without worsening of fibrosis compared to 10% in the placebo group (difference of 46 percentage points; P<0.001).

Tirzepatide may be an effective treatment option for patients with MASH and moderate to severe fibrosis.

In the 5-mg tirzepatide group, 44% of participants achieved resolution of MASH without worsening of fibrosis compared to 10% in the placebo group (difference of 34 percentage points; P<0.001).

Tirzepatide may be an effective treatment option for patients with MASH and moderate to severe fibrosis.

Comprehensive lifestyle interventions effectively decrease the incidence of type 2 diabetes in high-risk patients.

Practitioners should consider implementing comprehensive lifestyle interventions for patients at high risk of developing type 2 diabetes.

Intensive lifestyle modification decreased the incidence of diabetes by 6.2 cases per 100 person-years during a 3-year period.

Encouraging lifestyle changes can significantly reduce the risk of developing diabetes.

Intentional weight loss, particularly when substantial, lowers cardiovascular disease risk among people with overweight/obesity.

Weight management strategies should be emphasized in clinical practice to reduce CVD risk.

Treatment with once-weekly injectable semaglutide resulted in a mean change in body weight of -13.7% compared to -3.2% with placebo (P<0.001).

Semaglutide may be an effective treatment for weight loss in obese individuals with knee osteoarthritis.

Semaglutide treatment led to a mean change in the WOMAC pain score of -41.7 points compared to -27.5 points with placebo (P<0.001).

Semaglutide may significantly reduce pain in obese individuals with knee osteoarthritis.

Participants in the semaglutide group had a greater improvement in SF-36 physical-function score (mean change, 12.0 points) compared to the placebo group (mean change, 6.5 points; P<0.001).

Semaglutide may improve physical function in obese individuals with knee osteoarthritis.

Replacing high-glycemic-index carbohydrates with low-glycemic-index forms can improve glycemic control in diabetic patients.

Diabetic patients should consider dietary changes to include more low-glycemic-index foods for better glycemic control.

Fewer antidiabetes medications were used in the bariatric surgery group compared to the medical/lifestyle management group.

Bariatric surgery may reduce the need for diabetes medications compared to lifestyle management.

Ingesting protein with carbohydrate during recovery from aerobic exercise increased muscle fractional synthetic rate (FSR) to 0.09%/h compared to 0.07%/h with carbohydrate only and 0.06%/h with higher carbohydrate intake.

Practitioners should consider recommending protein coingestion with carbohydrates for enhanced muscle recovery post-exercise.

Whole body net protein balance (WBNB) was positive only during the protein and carbohydrate coingestion trial.

Incorporating protein with carbohydrates post-exercise can enhance overall protein balance, beneficial for recovery.

Higher weight loss was associated with a lower hazard of discontinuation for both patients with and without type 2 diabetes.

Encouraging weight loss may improve adherence to GLP-1 RA therapy.

The mean weight loss after 3 months of semaglutide treatment was 6.7 kg, equivalent to 5.9%.

Practitioners can expect significant weight loss in patients treated with semaglutide over 3 months.

The mean weight loss after 6 months of semaglutide treatment was 12.3 kg, equivalent to 10.9%.

Practitioners can expect continued weight loss in patients treated with semaglutide over 6 months.

87.3% of patients achieved weight loss of 5% or more after 6 months.

Practitioners can expect a high proportion of patients to achieve at least 5% weight loss with semaglutide.

Total ultra-processed food (UPF) intake is associated with a 46% higher risk of type 2 diabetes (T2D) when comparing extreme quintiles of intake.

Reducing UPF consumption may lower the risk of developing type 2 diabetes.

Interval training with work bouts at 85% peak power (PP) enhances 40-km time-trial performance by 2.8%.

Coaches should consider incorporating interval training at 85% PP to improve cycling time-trial performance.

Intervals performed at 175% peak power (PP) also improve time-trial performance by 2.4%.

Incorporating high-intensity intervals at 175% PP can also be beneficial for improving cycling performance.

VO2peak increased by 10% after 31 days of training.

Prolonged endurance training can lead to significant improvements in aerobic fitness.

Habit formation interventions have shown promising effects on behavior.

Incorporating habit formation techniques can enhance the effectiveness of behavior change programs.

Habit formation interventions may help displace existing bad habits with good ones.

Practitioners can utilize habit formation strategies to replace negative behaviors with positive ones.

Mean response time to reach 63% of steady-state VO2 was faster at 4 days (34.9 +/- 2.4 s) and 9 days (32.5 +/- 1.8 s) of training compared to pretraining (38.1 +/- 2.6 s), and was fastest at 30 days (28.3 +/- 1.0 s).

Endurance training can lead to quicker VO2 responses within the first month, which may enhance performance in submaximal exercise.